
Policy & Acquisitions
Mergers & Acquisitions
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Mergers & Acquisitions
Mergers & AcquisitionsLexeo Expands Friedreich Ataxia Pipeline With Mantle AcquisitionLexeo Therapeutics is expanding its Friedreich ataxia pipeline through the acquisition of Mantle Therapeutics and three CNS-focused collaborations.Fact-Checked
Mergers & AcquisitionsEnvisagenics, Boehringer Partner on RNA Splicing Cancer TargetsEnvisagenics and Boehringer Ingelheim have entered a multi-year collaboration to validate tumor-specific RNA splicing targets identified by the AI-powered SpliceCore® platform for potential precision oncology therapies.Fact-Checked
Mergers & AcquisitionsAbbVie and Iambic Partner to Accelerate AI-Driven Small-Molecule Drug DiscoveryAbbVie and Iambic have launched a multi-year collaboration to apply Iambic’s AI platform to small-molecule drug discovery across oncology, immunology and neuroscience, targeting candidates with first-in-class and best-in-class…Fact-Checked
Mergers & AcquisitionsTelix to Acquire ITM in $1.65 Billion Radiopharmaceutical DealTelix Pharmaceuticals will acquire ITM Isotope Technologies Munich for $1.65 billion in upfront consideration, with up to $700 million in additional milestones.Fact-Checked
Mergers & Acquisitions1ST-104 Parkinson’s Drug Licensed by SK Biopharmaceuticals1ST Biotherapeutics has licensed 1ST-104, an oral Type 2 LRRK2 and c-Abl dual inhibitor for Parkinson’s disease, to SK Biopharmaceuticals in an agreement valued at up to $314.8…Fact-Checked
Mergers & AcquisitionsRoche, Dualitas Launch Bispecific Antibody Discovery DealRoche and Dualitas Therapeutics have entered a major bispecific antibody discovery collaboration to screen more than 300,000 novel combinations for immunology and inflammation diseases.Fact-Checked
Mergers & AcquisitionsLisata Acquires Marea, Raises $225M for Cardioendocrine Drug DevelopmentLisata Therapeutics has acquired Marea Therapeutics in a stock-for-stock transaction and separately secured $225 million in financing to advance MAR001/005 and MAR002 through key clinical milestones.Fact-Checked
Mergers & AcquisitionsNovo Nordisk and Anthropic Partner to Accelerate AI-Driven Drug DiscoveryNovo Nordisk and Anthropic are collaborating to apply advanced AI models, including Claude Science, to pharmaceutical R&D, biological reasoning and software development, with initial testing focused on selected…Fact-Checked
Mergers & AcquisitionsGSK to Acquire Chimagen’s Trispecific T-Cell Engager for Multiple MyelomaGSK has agreed to acquire Chimagen Biosciences’ trispecific T-cell engager for multiple myeloma. The programme targets T cells and two tumour-associated antigens and is expected to enter Phase…Fact-Checked
Mergers & AcquisitionsHUTCHMED Licenses KRAS-EGFR Therapy to GSK in $1.3 Billion DealHUTCHMED has licensed global rights outside Greater China to HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate, to GSK in a deal worth up to $1.295 billion.Fact-Checked
Mergers & AcquisitionsDualityBio, Genentech Strike ADC Deal Worth More Than $1 Billion in Potential MilestonesDualityBio and Genentech have entered a global ADC collaboration centered on the DUPAC novel-payload platform, targeting resistance to topoisomerase inhibitor-based ADCs.Fact-Checked
Mergers & AcquisitionsMcKesson to Acquire Precision Medicine Group for $2.25 Billion, Expanding Clinical Research and Biopharma ServicesMcKesson will acquire Precision Medicine Group for approximately $2.25 billion, expanding its clinical research, biomarker, laboratory, market access and biopharma commercialization capabilities within its Oncology & Multispecialty business.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.